Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to “Strong-Buy” at Zacks Research

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a note issued to investors on Monday, Zacks reports.

A number of other research firms also recently weighed in on REGN. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Guggenheim increased their target price on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Leerink Partners raised their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research report on Monday, August 17th. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, HSBC upped their price target on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $802.18.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $750.51 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The company has a 50-day moving average of $782.91 and a 200-day moving average of $720.82. Regeneron Pharmaceuticals has a 52 week low of $541.00 and a 52 week high of $859.34. The company has a market capitalization of $77.27 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 1.47 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Envestnet Asset Management Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.6% in the second quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock valued at $68,488,000 after acquiring an additional 686 shares during the last quarter. Andra AP fonden increased its position in Regeneron Pharmaceuticals by 583.2% in the second quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock worth $18,028,000 after purchasing an additional 24,680 shares during the period. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares during the last quarter. Tidal Investments LLC raised its holdings in Regeneron Pharmaceuticals by 10.7% during the 2nd quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock worth $27,371,000 after purchasing an additional 4,244 shares during the last quarter. Finally, National Pension Service lifted its position in Regeneron Pharmaceuticals by 2.2% during the 2nd quarter. National Pension Service now owns 379,815 shares of the biopharmaceutical company’s stock valued at $236,830,000 after purchasing an additional 8,264 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sell-side analysts collectively rate Regeneron a “Moderate Buy,” indicating that the broader analyst consensus remains favorable. Regeneron also compares attractively on valuation against some biotechnology peers. Regeneron Pharmaceuticals Stock Rated Moderate Buy by Sell-Side Analysts
• Positive Sentiment: Biohaven has begun enrolling patients in a combination study pairing its investigational cancer therapy BHV-1530 with Regeneron’s Libtayo. The agreement could support additional development opportunities for Libtayo, though the program remains early stage. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results on October 30. The upcoming earnings release may provide updates on Eylea demand, guidance and the company’s broader pipeline, making it a near-term catalyst. Should You Buy Regeneron Pharmaceuticals Stock Before October 30?
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for two potential wet age-related macular degeneration treatments. The candidates met primary endpoints versus Eylea and may offer dosing approximately every six months, compared with Eylea’s current roughly eight-week schedule. The data raise the prospect of longer-term competitive pressure on Regeneron’s key eye-care franchise and prompted a sharp rally in Kodiak shares. Kodiak Skyrockets on Positive Study Data for Two Eye Drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “Sector Perform” rating and set a $737 price target, below the referenced share price, signaling limited near-term upside in that analyst’s view. Regeneron Sector Perform Rating Reaffirmed by RBC

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.